Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge is advising Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray receives issue proceeds of approximately SEK 135 million before deduction of transaction costs.
December 03, 2024

Vinge has represented Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB

 Vinge has represented the leading infrastructure group Eleda in connection with the acquisitions of Marbit Aktiebolag, FlexiRail AB, and Hanell Entreprenad i Gävle AB from Vestum. These companies are engaged in contracting activities within the construction sector. The total purchase price for the shares amounts to 747 MSEK. All key executives in the companies will become shareholders in Eleda.
December 02, 2024

Vinge has advised Fortum in connection with the divestment of its recycling and waste business

 Vinge, alongside among others Castrén & Snellman, has advised Fortum in connection with the divestment of its recycling and waste business to Summa Equity through its portfolio company NG Group. The debt free purchase price is approximately EUR 800 million.
December 02, 2024